Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH2 Gene Mutation”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Early research (Phase 1)Study completedNCT02481154
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Who this might be right for
Glioma
Institut de Recherches Internationales Servier 95
Testing effectiveness (Phase 2)Study completedNCT02273739
What this trial is testing

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Who this might be right for
Solid TumorGliomaAngioimmunoblastic T-cell Lymphoma+2 more
Celgene 21
Testing effectiveness (Phase 2)Looking for participantsNCT06577441
What this trial is testing

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Who this might be right for
Myelodysplastic Syndrome
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Looking for participantsNCT03383575
What this trial is testing

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839
What this trial is testing

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Who this might be right for
Acute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more
Shen yang 148
Early research (Phase 1)WithdrawnNCT04955938
What this trial is testing

Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Who this might be right for
IDH MutationIDH1 MutationIDH2 Gene Mutation+2 more
University of Chicago
Not applicableUnknownNCT03204838
What this trial is testing

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Who this might be right for
Acute Myeloid Leukemia (AML)
Hospital General de Mexico 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06478212
What this trial is testing

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Who this might be right for
IDH1-mutant GliomaIDH2-mutant Glioma
Institut de Recherches Internationales Servier 51
Not applicableLooking for participantsNCT07315542
What this trial is testing

Diagnostic and Therapeutic Targets in Cartilaginous Tumours

Who this might be right for
ChondrosarcomasCartilage Tumours
St. Anne's University Hospital Brno, Czech Republic 300
Testing effectiveness (Phase 2)Looking for participantsNCT05588141
What this trial is testing

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Who this might be right for
Brain TumorCancer
National Cancer Institute (NCI) 96
Testing effectiveness (Phase 2)Looking for participantsNCT03683433
What this trial is testing

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Who this might be right for
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Temporarily pausedNCT03728335
What this trial is testing

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Who this might be right for
Acute Myeloid Leukemia
City of Hope Medical Center 35
Early research (Phase 1)UnknownNCT04806659
What this trial is testing

SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous Leukemia
Nanjing Sanhome Pharmaceutical, Co., Ltd. 41
Testing effectiveness (Phase 2)Looking for participantsNCT06176989
What this trial is testing

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Who this might be right for
Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04203316
What this trial is testing

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Children's Oncology Group 1
Testing effectiveness (Phase 2)Ended earlyNCT04092179
What this trial is testing

Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

Who this might be right for
Acute Myeloid LeukemiaRelapsed CancerRefractory Cancer+1 more
University Health Network, Toronto 27
Testing effectiveness (Phase 2)Looking for participantsNCT07286292
What this trial is testing

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

Who this might be right for
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Institut de Recherches Internationales Servier (I.R.I.S.) 10
Not applicableUnknownNCT03499912
What this trial is testing

Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy

Who this might be right for
Acute Myeloid Leukemia
National Taiwan University Hospital 300
Large-scale testing (Phase 3)Study completedNCT02577406
What this trial is testing

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Who this might be right for
Leukemia, MyeloidIsocitrate Dehydrogenase
Celgene 319
Next Page